Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Irradiation-radiotherapy plus Zevalin and Bexxar immunotherapies with a.o. shows excellent approach for certain forms of cancer, including non-Hodgkin's lymfklier. Recent study added. Article update 11 January 2012
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Already in 2004 we received the following information of the ring, then producer, about Schee Zevalin. Zevalin is now a General approved in lymfklier forms of cancer, including non-Hodgkin 's. If you type gets you a range of Zevalin in pubmed studieabstracten. all too many to mention here. What is interesting here is to mention is a
article outline of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report. Down state writing Schee ring over Zevalin from 2004.
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
Zevalin, an immunological means (vaccine) in addition to irradiations
dated 21 January 2004:
Source: press release of Schee ring
Zevalin an immunological means to use besides irradiations of non-Hodgkin has received permission from the European Commission as officially registered to medication may be used. The results from a randomized phase III study were: 143 patients with repeated relapse of non-Hodgkin's were divided into two groups.
At the Group of patients who got Zevalin responded 80% on this medication versus 56 percent in the group that got Rituxan only administered. 30% of the Zevalin group got a complete remission and 4 percent a unconfirmed complete remission versus 16% and 4% respectively in the other group. These results are considered significant.
The remission in patients lasted about four trials given nearly two years with a number of patients to 6.5 years showed no relapse. This seems to be very good news, on the other hand is here also the snag with Zevalin is a remission achieved but often no definitive cure. But anyway this is a step forward again companies.
Also read once the story of mw. Bruins who only diet and supplementation for years now has no relapse of non-Hodgkin 's.
CAMBRIDGE, mass. and SAN DIEGO, Calif., Jan. 22 (Nasdaq: BIIB)/PRNewswire-FirstCall/--Biogen Idec today announced that the European Commission has granted marketing approval for ZEVALIN (Ibritumomab tiuxetan) radioimmunotherapy (R). ZEVALIN is approved in Europe for the treatment of adult patients with CD20 + follicular B-cell non-Disease lymphoma (NHL) who are refractory to or have relapsed following RITUXAN (rituximab) therapy (R). ZEVALIN was approved in February 2002 by the U.S. Food and Drug Administration (FDA). It is marketed and distributed by Biogen Idec in the U.S. Schering AG, Biogen Idec's corporate partner, holds marketing and distribution rights for ZEVALIN outside the U.S. and expects to launch the product in Europe within the next few months.
"Radioimmunotherapy ZEVALIN represents a major advancement in the treatment of certain lymphomas non-Disease," said Burt Adelman, Executive Vice President, Development for Biogen Idec. "We are pleased that through this partnership with Schering AG, patients in Europe will soon have access to this innovative therapy." Radioimmunotherapy is a new area of cancer treatment that combines the targeting power of monoclonal antibodies with the cell-damaging ability or localized radiation. ZEVALIN is made by linking monoclonal antibodies to radioactive isotopes. When infused into a patient, these antibodies circulate in the body radiation-carrying until they locate and bind to the surface of specific cells, and then deliver their cytotoxic radiation directly to malignant cells. ZEVALIN binds to malignant and normal B-cells. Normal B-cells generally are replenished by progenitor cells within six-to CD20-negative-nine months following therapy.
About Clinical Studies
Extensive clinical studies have confirmed high response rates and durable ZEVALIN or responses in patients with relapsed or refractory B-cell NHL, follicular transformed:
--In a Phase 2 study evaluating patients with follicular NHL who did not respond to or responded inadequately to ZEVALIN produced an overall response rate of RITUXAN, 74 percent, with 15 percent of patients achieving a complete remission (disappearance of all evidence of disease), according to International Workshop Response Criteria (IWRC). --A pivotal Phase 3 randomized, controlled trial was conducted in 143 patients with relapsed or refractory, low-grade or follicular NHL or transformed B-cell NHL. The 73 patients who received the ZEVALIN regimen showed an overall response rate of 80 percent, compared to 56 percent in the 70 patients who received RITUXAN alone. Thirty percent of ZEVALIN patients achieved a complete remission and 4 percent achieved an unconfirmed complete remission to therapy, compared to 16 percent of RITUXAN patients who achieved a complete remission and 4 percent who achieved an unconfirmed complete remission. The improvement in ORR and CR were statistically significant.
--ZEVALIN has been shown to induce durable remissions in many patients with relapsed or refractory B-cell NHL, as evidenced by long-term follow-up of complete responders from four registrational clinical trials. The median duration of remission for these patients approached two years, with some responses still ongoing at 75 months (6.25 years). --Thirty-seven percent of the responding patients treated in the registrational trials achieved long-term responses, defined as time to progression or longer than 12 months. Among these long-term responders, the median duration of response was 28.1 months.
--The registrational trials or ZEVALIN involved more than 30 academic and community cancer centers in the U.S. and included the only randomized clinical trial to date comparing radioimmunotherapy to another standard therapy. A high proportion of the patients in the trials were greater than 60 years old and had received three or more prior therapies. Schering AG, Germany is currently investigating the use of ZEVALIN in the treatment of aggressive NHL (i.e. diffuse large B-cell lymphoma,) and as consolidation therapy for follicular NHL in earlier disease internships.
About ZEVALIN
On February 19, 2002, the FDA approved ZEVALIN, a new type or targeted cancer therapy called radioimmunotherapy, making it the first commercially available radioimmunotherapy for the treatment of B-cell non-Disease lymphoma (NHL). A unique treatment regimen for patients with certain types of B-cell NHL, the ZEVALIN therapeutic regimen combines a monoclonal antibody with a radioisotope. The monoclonal antibody in ZEVALIN recognizes and attachés to a particular cell-surface part or a B-cell called the CD20 antigen. This allows ZEVALIN to specifically target B-cells, destroying the malignant NHL B-cells and also normal B-cells. ZEVALIN, as part of the ZEVALIN therapeutic regimen, is indicated in the U.S. for the treatment of relapsed or refractory, low-grade or follicular, transformed B-cell NHL RITUXAN refractory follicular NHL, including patients with.
Today, ZEVALIN is being investigated in multiple clinical trials at major medical centers in the U.S. and in a variety of treatment strategies, including combinations with front-line and salvage chemotherapy regi man and as part of
autologous and allogeneic stem cell transplantation.
ZEVALIN Safety Profile
In safety data based upon 349 patients, the most serious adverse reactions or the ZEVALIN therapeutic regimen were primarily hematologic, with grade 4 neutropenia, thrombocytopenia, and anemia occurring in 30 percent, 10 percent and 3 percent of patients treated at the 0.4 mCi/kg dose, respectively. Infusion-related toxicities were typically grade 1 or 2 and were associated with pre-Rituximab (RITUXAN) or administration. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Seven percent of patients were hospitalized with infection or febrile neutropena (3 percent) and fatal cerebral hemorrhage (less than 1 percent) has occurred in a minority of patients in clinical studies. The annualized rate for the development of treatment-related myelodysplasia or acute myelogenous leukemia is less than 1 percent of patients and can occur at 8 to 34 months after treatment.
ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides. Fatal Infusion Reactions: Rare deaths have occurred within 24 hours of Rituximab infusions. These fatalities were associated with an infusion reaction symptom complex that included hypoxia, pulmonary infiltrates, acute respiratory distress syndrome,
myocardial infarction, ventricular fibrillation, or cardiogenic shock. Prolonged and Severe Cytopenias: Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients.
